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A B S T R A C T
Genetic determinants of common human diseases are still poorly understood. Due to
large investments, many small successes have been made and the research field is ra-
pidly expanding. However, genetic susceptibility variants showing repeatable associa-
tions with common diseases are usually of small effect. They are therefore unlikely to in-
dividually explain substantial share of disease burden in any community or provide
new insights into disease pathogenesis that could lead to development of new drugs ef-
fective in considerable portion of the disease cases in a population. Genetic architecture
of common diseases is beginning to reveal an incredible diversity of potential genetic
causes that act through somewhat limited number of mechanisms with important con-
tribution of environmental interactions. In light of these findings, we present current
understanding of genetic architecture of a spectrum of human diseases. We address the
encountered problems in susceptibility gene identification, review the success of leading
gene identification strategies and discuss current prospects for translating genomic ad-
vances into measurable public health benefits.
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Introduction
Human health is defined by the World
Health Organisation as »...a state of com-
plete physical, mental and social well-be-
ing and not merely the absence of disease
or infirmity.«1. Critics of this definition
argue that health is a process rather than
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a state, and that well being cannot ever
be expected to be »complete«2. This shows
how difficult it is to define either health
or disease and to clearly separate them.
Human diseases represent a complex
spectrum of health disturbance, ranging
from those presenting early in life to tho-
se with very late onset and from mainly
genetically determined to nearly entirely
caused by environmental exposures3.
It is certain, however, that the aetiolo-
gy of some diseases is considerably sim-
pler than of the others. Some diseases
present in first days of life, limiting the
importance of environmental exposures
(apart from intrauterine) in their aetiolo-
gy. Such diseases are usually due to struc-
tural or functional deficiency of a single
protein, resulting from random change in
genetic code controlling the synthesis of
this protein4. The deficit of a single en-
zyme, or a building protein, eventually
leads to cascade of events presenting as
disease phenotype. In this case, in all af-
fected patients the disease phenotype is a
direct consequence of a single change in
genetic information. At the other end of
the complexity spectrum are diseases su-
ch as cardiovascular disease and cancer.
They develop for years as a result of the
combination of inherited polygenic sus-
ceptibility and lifetime exposure to the
environment3. Their slow development
can only be monitored as a gradual break-
down of physiological mechanisms that
became unable to compensate for micros-
copic structural damage or functional
changes at various levels of human orga-
nism. The result is a continuing deviation
of monitored metabolic or biochemical pa-
rameters from the expected value. Over
the course of time, this results in the first
presenting symptoms and eventually
leads to the development of characteristic
disease phenotype3.
The investigation of genetic and envi-
ronmental factors that interact in caus-
ing a disease has been a fundamental
goal of modern epidemiology of non-com-
municable diseases. This science recogni-
ses that each human being has different
genetic build-up (except monozygotic
twins) and personal history of lifetime en-
vironmental exposures, and therefore
represents unique evolutionary experi-
ment in time and space. However, by de-
signing appropriate prospective and ret-
rospective studies, modern epidemiology
attempts to identify genetic characteris-
tics and environmental exposures that
are significantly more frequent among
the persons with disease phenotype than
in general population. Such characteris-
tics, found among those who exhibit dis-
ease phenotype more frequently than it
would be expected by chance, are then
considered »disease risk factors«. Once
the risk factors are identified, evaluation
of the relative contribution of each of
them to the development of disease and
assessing whether the associations found
between diseases and risk factors are
causal or coincidental represent other im-
portant goals of modern epidemiology5–8.
To produce results of any validity, epi-
demiological studies heavily rely on in-
vestigator’s ability to precisely measure
suspected risk factors (genetic character-
istics or environmental exposures) and
correctly classify study subject according
to the presence or absence of the disease.
Presence of disease is typically »measu-
red« by a set of diagnostic criteria. Those
criteria have validity of nearly 100% for
many diseases (especially if based on pat-
hohistological examinations or various
biochemical tests). Still, for some common
diseases, misclassification is a serious
concern even nowadays9,10. Regarding the
risk factors, the researchers usually in-
vestigated those that could be measured
to any degree of precision. This included a
multitude of variables related to individ-
ual’s environmental exposures, physiolo-
gical or metabolic monitoring, or even
psychological profiling. The most investi-
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gated risk factors in non-communicable
disease epidemiology during the 20th cen-
tury therefore included person’s age, ma-
rital status, occupational exposures, smo-
king, body mass index, blood pressure,
cholesterol levels, food intake frequency,
psychological assessment of life quality,
etc. This all fostered development of envi-
ronmental, ecological, occupational, nut-
ritional and psychological epidemiology5.
Genetic epidemiology, however, was
unable to expand in a similar fashion.
This was because during most of the 20th
century it was hardly possible to measure
individual’s genetic build-up in any direct
way. Investigation of genetic risk factors
was limited to twin studies11, heritability
studies12, inbreeding studies13 and stud-
ies of phenotypically expressed genetic
variation (e.g. classic erythrocyte anti-
gens, HLA systems)14,15. Those studies
had a variety of designs and could only
provide indirect insights into general pat-
terns of association between factors rela-
ted to inheritance and occurrence of dis-
eases. This was very far from designs
that researchers ideally desired to apply.
However, this situation dramatically
changed during the past two decades,
when first methods for the analysis of the
variation in the DNA molecule in each
human individual were introduced16,17.
Such development immediately attracted
epidemiologists of non-communicable dis-
eases, who realised the opportunities pro-
vided by directly measuring genetic ma-
terial as a disease risk factor6. The early
excitement and optimism were justified,
as today it is possible to measure individ-
ual’s genetic build-up more precisely than
we will ever be able to measure person’s
environmental exposures, such as nutri-
tion or psychology. The progress in geno-
mic research, especially in understanding
the patterns of variation in the human
genome, is destined to nurture further ra-
pid expansion of genetic (genomic) epide-
miology, possibly to the levels that even-
tually may surpass all historic successes
of other approaches to epidemiological re-
search in non-communicable diseases18–21.
In this text, current strategies to find
genes responsible for susceptibility to hu-
man diseases will be discussed, especially
those associated with the greatest burden
of disability and death, such as cardiovas-
cular diseases, cancer, diabetes or psychi-
atric disorders. The ongoing debates on li-
kely genetic architecture of most common
human diseases will be addressed, and
the suitability of the available tools to
find underlying genes to the existing
knowledge gathered from both genetic
and epidemiological research of human
disease aetiology will be analysed. Final-
ly, based on the results of various applied
strategies to find common disease suscep-
tibility genes, current prospects for trans-
lating genomic advances into measurable
public health benefits will be discussed.
Advances in Genome Research
Enhanced Development of Genetic
Epidemiology
The main goal of genetic epidemiology
is to express genetic build-up of an indivi-
dual as a (predictor) variable, so that it
could be statistically correlated to other
variables of interest – disease phenotype
and interacting environmental risk fac-
tors. The criterion variable in this design
can be qualitative (presence or absence of
disease phenotype) or quantitative (such
as levels of blood pressure, serum choles-
terol or blood glucose). The advances in
study of the human genome during 1990’s
through publicly funded Human Genome
Project (HGP) and privately funded pro-
ject at Celera Genomics made important
steps towards achieving this goal22,23.
The sequencing of the human genome
showed that all humans are identical in
about 99.9% of their genome sequence.
More importantly, however, the genes
(which are, in broad terms, the segments
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of the genome sequence that contain code
for protein synthesis) formed only about
3% of that sequence, while the function of
the remaining 97% of the genome remai-
ned largely unknown.
After those discoveries, it seemed logi-
cal to assume that the entire variation in
terms of susceptibility to acquiring or
avoiding diseases during life span would
have to be due entirely to variation found
within those 3% of the coding genome se-
quence, i.e. the genes. Efforts by HGP
and Celera both estimated that there are
about 40,000 genes scattered across the
human genome22,23. The term »gene«,
however, has a number of possible defini-
tions. For the purpose of genetic epidemi-
ological studies »gene« can be considered
a location in human DNA molecule, usu-
ally several thousand nucleotides (i.e. ba-
se pairs) long, in which there is inter-
changeable repeat of shorter segments of
coding sequence (»exons«) and longer seg-
ments of non-coding sequence (»introns«).
During protein synthesis, the coding ele-
ments (»exons«) are first transcribed into
»messenger RNA« (mRNA) molecule,
while the non-coding elements (»introns«)
are cut out. Messenger RNA then travels
from cell nucleus to ribosomes where it is
being read in »triplets« of nucleotides,
each encoding the subsequent amino-acid
to be built into the structure of a result-
ing protein. It is important to note that
location in DNA that we refer to as a »ge-
ne« jointly assumes the coding informa-
tion inherited from mother (one DNA
strain) and father (complementary DNA
strain). If those two sequences (»gene al-
leles«) inherited from both of the parents
are identical, then a person will be »ho-
mozygous« for that gene, and if they dif-
fer the individual is »heterozygous«. If bo-
th differing sequences (»alleles«) of a gene
in a heterozygous individual are eventu-
ally expressed in a phenotype, then they
act »codominantly«. If only one of them is
phenotypically fully expressed and the ot-
her is not, then they are »dominant« and
»recessive« alleles, respectively6,22,23.
The defined terms »homozygosity« and
»heterozygosity« refer to characteristic of
each gene in an individual. Genetic epi-
demiology is also interested in terms that
relate to characteristics of genes in the
entire population. A gene is »monomor-
phic« if there is only one (»fixed«) allele
for this gene present in the entire popula-
tion. This means that all the individuals
in the population will have to be homozy-
gous for that gene, as they will always in-
herit the same allele, whoever their par-
ents are. It is thought that about 65% of
all human genes are monomorphic. Those
probably include many genes with regu-
latory signalling function that determine
that we only should have two kidneys,
one liver and five fingers on each hand.
Other genes are »polymorphic«, as two or
more sequence variants (»alleles«), each
with population frequency of at least 1%,
can be found in the population at their
precise genomic location. The differences
between humans at their birth are thought
to be mainly due to genetic variants found
at polymorphic genomic loci22,23.
We argued that the goal of genetic epi-
demiology was to precisely measure gene-
tic build-up of each individual and to
quantitatively express it as a variable.
This means that genetic epidemiologists
are interested only in varying part of hu-
man genetic material. If we accept that
97% of non-coding human genome se-
quence has no apparent function, then
this part of the genome should not influ-
ence disease susceptibility. In addition to
that, some two thirds (27,000) of 40,000
human genes should be monomorphic
(»human genetic invariance«), and their
role in disease susceptibility therefore en-
tirely passive. This intuitively suggests
that only the differences in combinations
of alleles that can be found at remaining
13,000 polymorphic human genes deter-
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mine genetic variation in susceptibility to
human disease.
If this is true, it would reduce the aim
of genetic epidemiology to identifying dif-
ferent sequence variants (»alleles«) in po-
lymorphic genes that are significantly
more frequently present among the dis-
eased than in healthy population. Subse-
quent goals would then include under-
standing how the change in sequence
(»mutation«), which introduced this new
allele, affects protein synthesis, and by
what mechanisms does this lead to disea-
se phenotype. Therefore, finding alleles
associated with increased disease risk
could, in long term, allow genetic testing
of individuals at very early age and un-
dertaking preventive measures from child-
hood to decrease environmental disease
risks. Other apparent benefit of finding
these alleles is that insights into change
in function of the protein they encode
could enhance our understanding of com-
plex mechanisms that cause the disease
and provide new targets for development
of related drugs.
In an ideal genetic epidemiological
longitudinal study, all 13,000 polymor-
phic human genes would be sequenced in
the entire human population. All the ex-
isting sequence variants (»alleles«) would
be catalogued and their population fre-
quencies determined. Then, all humans
would be followed up for disease status
during their entire lifetime. After correct-
ing for known environmental risks, gene-
environment interactions and gene-gene
interactions, it would theoretically be
possible to assign relative risks and popu-
lation-attributable fraction of disease in-
cidence in the population to each allelic
variant that exists for each polymorphic
gene. This would currently be completely
impossible, as large funds and years of
work by many research groups would ha-
ve to be spent at the current state of tech-
nology to perform this study even in 10
individuals22,23. However, the costs of ge-
notyping (i.e. determining existing alleles
at different genome locations in DNA
from individual subjects) are rapidly dec-
reasing and the speed at which it can be
performed is increasing. This led to re-
cent calls to set the target at an affordab-
le price for whole genome sequencing, i.e.
setting a long-term goal to reduce the pri-
ce of sequencing each individual’s genome
to about $1,00024. This is still far from re-
alistic, but hardly anyone in the field
would argue that it might not become
possible in the future. Genetic screening
and individually tailored drug treatment
and prevention strategies could therefore
become available to everyone who could
afford the sequencing of his/her own ge-
nome.
Until then, we will have to design al-
ternative approaches to locate genes un-
derlying human diseases and find allelic
variants responsible for functional chan-
ges that lead to disturbed health. The
main problem is correctly associating dis-
ease phenotype with the specific allelic
variant of a gene located somewhere in a
genome. The advances in human geno-
mics offered first tools. These are based
on two fundamental properties of the hu-
man genome. The first is the existence of
several abundant classes of polymorphic
sites scattered across the entire genome
with precisely determined locations (»po-
lymorphisms«, »genetic markers«), that
can be genotyped using polymerase chain
reaction25–28. The second is a property of
the genome called »linkage disequilib-
rium«, which suggests that markers that
are physically close to each other will
tend to be co-inherited, and so will the en-
tire genomic sequence between them29–32.
Polymorphic Markers and Linkage
Disequilibrium Enabled Search for
Genes Responsible for Human Diseases
The sequencing of human genome pro-
duced evidence of general identity of ge-
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nomic sequence among humans in about
99.9%. However, this is not to say that all
6 billion people have nearly identical se-
quence, and that the entire observed vari-
ation is due to the remaining 0.1% of the
genetic code. It needs to be understood
that virtually any of the 3 billion nucleo-
tides in the haploid genome can be ran-
domly changed by mutation at any gener-
ation in any individual33. However, as
any person has 2 alleles for every gene
(apart from those on Y-chromosome), the
frequencies of such changes at the time of
their first appearance will be 1 in 12 bil-
lion alleles, i.e. negligible. We speak of
»polymorphic sites« in the human genome
only when such newly introduced muta-
tions gradually increase in population
frequency over a number of generations,
and eventually the frequency of the sec-
ond allele of a previously monomorphic
gene reaches frequency of at least 1% in
the entire population33. Loci with two or
several alleles present in the population,
each in frequency greater than 1%, have
been found at about 0.1% of human geno-
me sequence. These polymorphic sites
can be exactly located by applying specifi-
cally tailored restriction enzymes. There
are several classes of those »polymorphic
sites« in the genome (»genetic markers«,
»polymorphysms«), but we will only men-
tion two that have potential to be the
most important for finding genes respon-
sible for common human diseases.
The first class of polymorphisms is
jointly termed »short sequence repeats«
(SSR). At some locations in the genome,
short nucleotide sequences tend to repeat
several times (e.g. »TATATATA« repre-
sents a dinucleotide »TA« which is repea-
ted four times; »GTCGTCGTC« is a tri-
nucleotide »GTC« repeated three times).
For some reason, when DNA is duplica-
ted during the cell division, the number of
repeating times of these nucleotide se-
quences can be slightly mistaken (e.g. 6
or 8 repeats are transcribed into the DNA
of separating cell instead of 7). An obvi-
ous analogy is a tired pupil who has to re-
write a very long sequence of numbers
from one paper to another for his home-
work without making a single mistake.
When the numbers that follow each other
are diverse (e.g. 274930618…) it is easier
to do it correctly, as it is simple to go back
to the last transcribed number in case of
fall in concentration. However, when the
sequence involves repeating the same
number several times (e.g. 2866666678…),
it is easier to miscount how many times
does the number »6« repeat and to make a
mistake. If the original number sequence
and pupil’s homework were passed on to
hundreds of other pupils for re-writing, it
would eventually result in very few mis-
takes in the parts of the number sequence
which is diverse. However, the number of
»6« repeats at the particular line in the
paper would probably range anywhere
from 3 to 10. This is an analogy on how
diversity in SSR arose over the course of
human history. The locations in the geno-
me where variable number of short tan-
dem repeats can be found are called
»STR«-s (from »short tandem repeats«) or
»microsatellites«. The exact location of
hundreds of those »markers« has been de-
fined in the human genome, which roug-
hly translates into one per each 1 million
of nucleotides (bp). They are very infor-
mative, as not only are they variable in
population at each individual location,
but their sequence along the chromoso-
mes (termed »haplotype«) is becoming
more unique for each person with intro-
duction of each following microsatellite
into a haplotype. With each new polymor-
phic STR added, the probability of any
two persons sharing exactly the same
haplotype rapidly diminishes, until it is
so small that it allows unique identifica-
tion of each person based on variation
found in the DNA25,26,34.
Other large and promising class of po-
lymorphisms are »single nucletoide po-
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lymorphisms« (SNP). These have been
one of the major discoveries of the Hu-
man Genome Project. It is thought that
there should be several million of these
polymorphisms scattered throughout the
human genome33. We remind that each of
3 billion nucleotides in the human geno-
me can mutate (e.g. from »A« to »C«, »T«
or »G«), giving rise to a new »allele« of ex-
tremely low frequency in the population
(which equals exactly one over doubled
number of all humans). However, not ma-
ny of those mutations will increase in fre-
quency over many generations to reach
allele frequency of 1% needed for that
precise location in the genome to be for-
mally declared a »single nucleotide po-
lymorphysm« (SNP). It should be noted
that each individual SNP marker is inca-
pable to subdivide humans into as many
categories as each individual STR mar-
ker. This is because each SNP locus can
theoretically only have four different »al-
leles« (»A«, »C«, »T« or »G«), one of which
is usually highly predominant. At the sa-
me time, each STR marker can have nu-
merous alleles (e.g. 10 alleles with 5 to 14
repeats), many of them with quite similar
allele frequencies. This makes a haplo-
type of any 5 consecutive STR markers
far more informative, while any 5 consec-
utive SNP markers may be shared by a
large number of humans. However, the
advantage of SNP’s over STR’s is that
they are several orders of magnitude mo-
re numerous in the human genome, and
that one can be found roughly after every
1 thousand nucleotides, while one STR
can approximately be found per each 1
million nucleotides. Thus, SNP’s should
allow for very fine search for genes on se-
quence segments that have been suspec-
ted as candidate for harbouring disease
genes. This is often referred to as »fine-
mapping« and it uses the property of ge-
nome termed »linkage disequilibrium«,
which we will attempt to explain in more
detail35,36.
Human genome is diploid in nature,
which means that the large majority of
its 3-billion-nucleotide sequence exists in
duplicate, one copy inherited from each
parent. Those two copies coexist and fun-
ctionally represent a single human geno-
me. The only two exceptions to this rule
are the sequence of Y-chromosome (hap-
loid in nature and always inherited from
the father) and mitochondrial DNA (al-
ways inherited from the mother). The
rest of the human genome is diploid, and
it has the property of recombination
(»crossing over«): exchanging the corres-
ponding complementary segments of the
genome sequence between parents’ hap-
loid genome sequences in each person.
This happens during meiosis, when the
recombined 23-chromosome haploid ge-
nome does not contain exclusively single
parents’ chromosomes, but rather a rela-
tively random mixture of maternal and
paternal sequence within each chromoso-
me. This has the obvious consequence of
breaking down the haplotypes of specific
STR or SNP markers that were originally
found along the paternal chromosomes.
However, polymorphic alleles on a haplo-
type that are physically close to each ot-
her will have smaller probability of sepa-
ration through recombination from those
that are located far apart. Therefore, so-
me alleles will have a probability of co-in-
heritance greater that the expected of
50%, as if they were on different chromo-
somes or recombination could occur ran-
domly between them. For such alleles
that remain together on a paternal haplo-
type (»unrecombined«), we say that they
are in »linkage diseqilibrium«29–32.
An illustrative example to explain the
relationships between polymorphic mar-
kers, a newly introduced mutation (»dis-
ease gene«) and linkage disequilibrium in
the population over a course of human
history is based on the analogy with the
deck of 52 cards. Let us suppose that a di-
sease gene arose somewhere in the geno-
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me of a single individual. If we had a deck
of 52 cards (»polymorphic markers«) to in-
sert at known positions in the genome of
this individual, those cards could help us
find the responsible gene several genera-
tions later, among all the diseased des-
cendants in the population. Let us suppo-
se that we chose to neatly order all the
cards by colour and rank along the geno-
me in which the disease mutation initial-
ly developed. Then, a Joker (»disease mu-
tation«) is randomly inserted between
Queen and Jack of Hearts. Now, in each
mating (»generation«) another deck of
cards will be placed next to this original
deck, with its cards in completely random
order, and three cards at random posi-
tions from 1–52 will be exchanged be-
tween the two decks (»recombination«).
Then, our original deck (»haploid geno-
me«) will be passed on to the next genera-
tion, in which Joker will again lead to dis-
ease. After repeating this procedure 5–10
times (»generations«), it will still be likely
that some pairs, triplets or even quintets
of cards (»haplotypes«) that originally fol-
lowed each other by colour and rank in
the first deck still do now. This would
mean that they are in »linkage disequilib-
rium«, and that exchange (»recombinatio-
n«) did not entirely destroy the original
card order (»haplotype«). It would also
mean that the Joker can probably still be
found between (»linked to«) both Queen
and Jack of Hearts, or hopefully at least
next to one of them, unless they were
among the cards exchanged.
However, if the original deck of cards
was multiplying after each exchange, and
if Joker (»disease gene«) was invisible by
being pulled out at some point, we could
still locate where it was originally inser-
ted. This is because both Queen and Jack
of Hearts would be unusually frequently
present at their original positions in ma-
ny decks that had Joker, while all the ot-
her cards would be entirely random. This
would make us reasonably sure it had to
be located between those two cards. How-
ever, after this procedure is repeated long
enough, the original order of cards will
eventually completely diminish (»decay of
linkage disequilibrium over time«): any
card could be found at any position. After
many thousand repeats of this procedure
and multiplying of the resulting deck, we
would not be able to find Queen and Jack
of Hearts (»polymorphic markers in link-
age disequilibrium with disease gene«) at
their original position more frequently
than expected by chance.
Study Designs of Genetic
Epidemiology: Linkage Analysis
versus Genetic Association Studies
Based on this understanding and defi-
nition of polymorphic markers and their
positions, first genetic epidemiological
study designs aiming to find alleles res-
ponsible for diseases could begin to emer-
ge. Two types of studies were most obvi-
ous choices: one based on collection of
families in which disease phenotype was
clustering (»linkage analysis«), and the
other based on sampling of affected indi-
viduals and unaffected controls from the
entire population (»genetic association
studies«). Both of those approaches were
made possible by development of so-cal-
led »linkage maps«, i.e. sets of hundreds
of STR markers intended for »genome-wi-
de scan«. These »genome-wide scans« ai-
med to identify at least one marker, but
preferably the specific haplotype, that
would be found in excessive frequency
(with extremely high statistical signifi-
cance) among affected disease cases in
comparison to unaffected controls. The
controls would come from either unaffec-
ted close relatives (»linkage analysis«) or
random unaffected individuals from the
population (»genetic association stud-
ies«). When a marker was found in excess
frequency among affected individuals in
comparison to controls, it would then be
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presumed that it must be physically »lin-
ked« to disease gene. Then, the whole
»candidate« region around the marker
would be fine-mapped by more dense set
of markers to identify the precise position
of the responsible gene37.
Historically, »linkage analysis« has
proven to be a very successful and power-
ful approach if several realistic require-
ments were fulfilled. Firstly, it was neces-
sary to collect a number of nuclear (or
extended) families with two or more dis-
ease cases. Secondly, it was essential that
the affected persons were correctly classi-
fied as »diseased« and unaffected as
»healthy«. Thirdly, all disease cases in
each family needed to be caused by muta-
tions in only one gene, resulting in appar-
ent pattern of disease inheritance (»Men-
delian« diseases: autosomal or sex-linked,
with dominant, recessive or codominant
mode of inheritance). Fourthly, there
should be no genetic heterogeneity in dis-
ease aetiology, meaning that all the dis-
ease cases in all collected families from
the population were caused by mutations
in the very same gene with unique posi-
tion in the human genome6,37.
If these requirements were met, find-
ing the markers linked to disease gene
and a »candidate region« around them
was reasonably simple. All of the individ-
uals from all of the families, regardless of
disease status, would first be »genotyped«
by »genome-wide scan«, i.e. the set of sev-
eral hundreds of STR markers (»microsa-
tellites«) would be determined in each in-
dividual. The average distance between
those markers used for such »genome-wi-
de scan« would typically be 5–10 centi-
morgans (see later). Then, suppose that
the investigated disease was dominantly
inherited and the father and two children
in the first collected family were affected,
but mother and the third child were unaf-
fected. It would then be closely monitored
which markers were shared between the
father and the two affected children, but
were absent in mother and the third
child. As father transmits a random 50%
of his genome to each of his children, this
single family would probably already ex-
clude more than 70% of studied markers
as potential candidates. Then, the second
recruited family would be subsequently
added to the analysis, followed by all the
others and each time further reducing
the possible candidate region of gene po-
sition. Eventually, only one marker or a
short haplotype would remain non-exclu-
ded, pointing to the location of a gene res-
ponsible for disease phenotype.
If the studied disease was recessive,
especially if it was found in an inbred pe-
digree (which was usually the case), link-
age analysis would be even more power-
ful. The gene would have to be in the
parts of the genome of the affected child
that is inherited identical-by-descent
from both parents38. In children of second
cousins, only 1.25% of the genome is ex-
pected to be shared identical-by-descent,
so if 800 STR markers were used to locate
the gene, only about 10 of them would re-
main possible candidates after the analy-
sis of a single case and his parents. The-
refore, it was enough in some instances to
find only 3 cases from an inbred isolate
human population to be able to narrow
down a »candidate region« to a single
marker. Many genes for Mendelian disea-
ses were found in isolate and inbred hu-
man communities, as it was extremely li-
kely that the rare genetic mutation had
to be introduced at only one occasion in
history by a single founder39. Thus, gene-
tic heterogeneity of the studied disease
was not a concern, as was the case when
the families were collected from general
population.
After the candidate marker linked to
disease gene is identified, fine-mapping
of the surrounding region is performed
with more dense set of markers, involving
both STR's and SNP's. The density of se-
lected markers for both genome-wide
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scan and subsequent fine-mapping of spe-
cific gene is always an important issue in
any linkage analysis. As base pairs (nuc-
leotides) measure physical distance be-
tween positions in the genome, Morgans
measure the probability of recombination
occurring between them per meiosis (gen-
eration). This makes it more appropriate
measure of distance between markers
when they are used to locate the un-
known gene, whereby 1 million base pairs
roughly equals to 1 centimorgan (cM)40.
The use of linkage set with markers that
are 5 cM apart meant that there was only
5% chance that recombination occurred
between those two markers during meio-
sis. The initial genome-wide scans are
therefore usually performed with marke-
rs spanning 5 or 10 cM, as this represents
acceptably low probability that the re-
combination destroyed connection between
the marker and disease gene, given the
large number of recruited families that
would eventually point to the region of in-
terest. Sometimes, however, especially in
inbred communities with large regions of
linkage disequilibrium, the eventually
determined candidate region spans over
the entire haplotype of several markers,
i.e. several megabases in distance, and
harbours hundreds of genes. Therefore, it
typically took years until the causal gene-
tic variant was found by fine mapping
and its function understood. However,
through this procedure a complete under-
standing of the aetiology of those diseases
was obtained, which would be impossible
by any other available means.
Genetic association studies are anot-
her obvious strategy for genetic epidemio-
logical research, possibly even simpler in
design. They rely on a hope that diseases
that will be commonly found in popula-
tion would have common allelic variants
causing them. Those common variants
should, ideally, all descend from a single
mutational event occurring in one person
in human history. In theory, this may be
possible if harsh selection was introdu-
ced. For example, in time of a catastro-
phic historic epidemics, a person could
have had a disease-causing mutation in
his genome located very close to (i.e., »in
linkage disequilibrium with«) important
and rare HLA variant that helped surviv-
ing the epidemics. The selection (»epide-
mics«) would then cause a massive reduc-
tion in the population size (»bottleneck
effect«), after which the frequency of fa-
vourable HLA variant would be dramati-
cally increased in surviving population,
but along with it also the unfavourable
disease-causing mutation. The other
mechanism through which susceptibility
variants for common diseases could have
reached high frequencies is »antagonistic
pleiotropy«: a variant that was positively
selected, because it controlled a fitness-
improving trait early in life, may have ne-
gative health effects in the post-reproduc-
tive period41. An apparent example of this
»thrifty genotype« hypothesis is type II
diabetes42. It is very likely that humans
were exposed to starvation throughout
most of their evolution, thus positively se-
lecting genetic variants for slow and hig-
hly efficient food metabolism. However,
large environmental changes during the
past century and general availability of
food in developed countries led to epidem-
ics of obesity later in life, which seems to
be the main determinant of type II diabe-
tes.
In genetic association studies, all that
is thought required to find the genes un-
derlying late-onset complex diseases
would be genotyping many disease cases
in the population and many unaffected
controls, until some differences in marker
allele frequencies begin to show significant
differences. Therefore, genetic associa-
tion studies are practically linkage analy-
ses where the entire population is consid-
ered a giant pedigree7,37. However, it is
still a matter of great debate if this ap-
proach is efficient, as it is based on the
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number of assumptions that in many ca-
ses may prove quite unrealistic8. This
will be further discussed in the chapter
on the leading current approaches to find
genes for complex diseases.
Recent Understanding of Genetic
Determinants of a Spectrum of
Human Diseases
A) Monogenic (Mendelian) Diseases
The common feature of »Mendelian«
diseases is that their entire phenotype is
caused by a rare mutation in a single ge-
ne in the genome. Therefore, the segrega-
tion of affected individuals in families fol-
lows simple Mendelian predictions4. The
catalogue of known Mendelian diseases is
regularly published and there are curren-
tly up to 8,000 listed diseases or syndro-
mes43. Last decade witnessed great suc-
cesses in identifying genetic variants
underlying about 1,200 of these disea-
ses11,44,45. The key property of Mendelian
diseases that made this success possible
is that causal genetic mutation is both
necessary and sufficient for the develop-
ment of disease. This ensures good corre-
lation between disease phenotypes and
underlying genotypes, given the penet-
rance of genetic effect is high, which is an
important requirement for successful lin-
kage analyses or genetic association stu-
dies44,45.
However, the initial successes in map-
ping variants underlying Mendelian dis-
eases were soon followed by unexpected
insight into the complexity of those »most
simple« diseases. Two examples that we-
re most extensively studied are retinitis
pigmentosa and thalassaemias. Follow-
ing the mapping of initial variants res-
ponsible for the phenotype of retinitis
pigmentosa in large pedigrees, it soon be-
came apparent that there are many diffe-
rent genes, perhaps dozens, scattered
throughout the genome, that may lead to
the same disease phenotype when muta-
ted. The aetiology of this condition proved
even more complex when it was recogni-
sed that numerous genetic variants that
underlie this condition follow very differ-
ent modes of transmission: autosomal do-
minant, autosomal recessive, sex-linked
dominant and sex-linked recessive37,46.
Perhaps the most comprehensive in-
sight into the complexity of phenotype-
genotype relationships in monogenic dis-
ease was given by Weatherall45. His stud-
ies on the thalassaemias across the world,
arising through positive selection as a
condition protective against deadly mala-
ria, but based on extremely different ge-
netic mechanisms, showed how a remark-
able diversity in phenotypes is encoun-
tered even in this relatively »simple« di-
sease45. Thalassaemias are probably the
commonest human monogenic diseases,
and approximately 7% of world’s popula-
tion are carriers for different inherited di-
sorders of haemoglobin. The extreme
phenotypic diversity of this condition en-
countered throughout the world is deter-
mined by »...layer upon layer of complexi-
ty«45. Firstly, there is a variety of primary
mutations at the beta-globin genes, simi-
larly to the example of retinitis pigmento-
sa. Then, there is the action of two known
»secondary genetic modifiers«: alpha and
gamma-globin genes, which affect the
magnitude of excess of alpha chains. The
result of the combined action of primary
and secondary modifiers is then affected
by an unknown number of less well defi-
ned »tertiary modifiers« (e.g. vitamin D
receptor, oestrogen receptor, genes impli-
cated in collagen synthesis, the locus for
hereditary haemocromatosis, UGT glucu-
ronyltransferase, HLA-DR locus, tumour-
necrosis factor alpha, intracellular adhe-
sion molecule 1)45. Finally, it is recogni-
zed that environment, ethnological and
cultural factors also strongly affect the
disease phenotype, although the underly-
ing mechanisms are less clear45. This all
shows the complexity underlying even
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the »simplest« of genetically determined
diseases and it should be taken into ac-
count when the studies searching for ge-
netic determinants of more complex dis-
eases are designed, which is not usually
the case.
B) »Oligogenic« Diseases
The initial successes in discovering ge-
netic variants underlying monogenic dis-
eases encouraged further progress with
the diseases that showed high heritabili-
ty and were thought to be simpler in aeti-
ology – »oligogenic diseases«. An excellent
example is Hirschprung's disease, which
is the most common hereditary cause of
intestinal obstruction. The pathogenesis
of the disease was roughly understood,
and the absence of ganglion cells in the
specific plexuses of gastrointestinal tract
(myenteric and submucosal) were impli-
cated as a cause47. This understanding
and the early onset of the disease led the
scientists to believe that Hirschprung di-
sease (HD) is mainly genetically determi-
ned and of relatively simple aetiology, al-
though the clear Mendelian pattern of
inheritance could not be established. The
efforts based on linkage analysis in pedi-
grees with multiple affected cases (»mul-
tiplex pedigrees«) led to insights which
categorised the disease by genetic aetiolo-
gy and explained both familial and popu-
lation risk of the disease48. There is the
more common »short segment« form (S-
HD), influenced by the three susceptibili-
ty loci at the chromosomes 3, 10 and 19,
that explain the complete population inci-
dence of this form of HD. The gene at
chromosome 3 is probably RET, which
seems to have the crucial role in all forms
of HD (but not both necessary and suffi-
cient, as is the case with other genes that
cause monogenic diseases). Other forms
of the disease (»long-segment« and »syn-
dromic« HD) are more rare and genetical-
ly more complex, with coding sequence
mutations in RET, GDNF, EDNRB, ED-
N3 and SOX10 genes being implicated in
various studies48.
Another disease that seems to show
»oligogenic« determination of susceptibil-
ity is perhaps also an unexpected one –
the leprosy. Although this disease is in-
fectious, the development of the pheno-
type seems to be strongly genetically de-
termined. A recent paper by Mira et al.49
showed how the association of the disease
with chromosomal region 6q25 was first
implicated in a sample of 86 Vietnamese
multiplex families using model-free link-
age analysis. The association of the can-
didate region was then repeated in 208
independent simplex Vietnamese fami-
lies consisting of both parents and one af-
fected child50. Fine mapping using single
nucleotide polymorphisms implied a reg-
ulatory region shared by genes PARK2
and PACRG as responsible for leprosy
susceptibility49. The authors further rep-
licated this association in a sample of 975
unrelated cases and controls from Brazil,
in whom the same variants also showed
significant association with leprosy in a
candidate gene study49. Another chromo-
somal region (10p13), earlier implicated
in an Indian sample of »paucibacillary«
disease cases51, also showed strong asso-
ciation in a »paucibacillary« subset of
Vietnamese cases, but not in the »multi-
bacillary« subset. The authors concluded
that variants in PARK2 and PACRG are
common alleles that confer susceptibility
to leprosy »per se« globally, and that vari-
ants in 10p13 region are also common al-
leles that determine clinical presentation
of disease as »paucibacillary« or »multi-
bacillary«49,50.
In recent years, more promising evi-
dence is being gathered suggesting that
some other diseases may have reasonably
simpler architecture of genetic suscepti-
bility than common complex diseases of
late onset. There is recently an increased
enthusiasm over the identification of va-
riants underlying the susceptibility of as-
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thma52–55, systemic lupus erythematosus56
and psoriasis57,58.
C) Complex Polygenic Diseases of
Late Onset
Genetic basis of common complex dis-
eases of late onset, responsible for most of
the public health burden in wealthy coun-
tries of the world, is currently perhaps
the greatest focus of interest of the entire
biomedical scientific community. This is
partly because identification of common
genetic risk variants in human populatio-
ns would enable genetic screening and
possibly provide new therapeutic targets
for drugs that could be administered in
the same manner to large number of per-
sons at increased risk. As both of those
prospects would certainly be extremely
lucrative and lead to unprecedented in-
crease in revenues for those producing
genetic tests and drugs, the investments
into search for genetic determinants of
common late-onset diseases have been
enormous during the recent years. Howe-
ver, the output to date was hardly propor-
tional to the investments. It appears that
apparent successes in mapping genes for
monogenic diseases and sequencing of
the human genome prompted large num-
ber of research groups, as well as both
private and public investors, into the »gold
rush« (search for the »Croesus Code«)
that may have been based on slightly over-
optimistic assumptions59. Primarily, the
common diseases of greatest interest, i.e.
cardiovascular disease, cancer, type II di-
abetes and psychiatric disorders, are fre-
quently extremely complex phenotypes
that are, contrary to most monogenic dis-
eases, difficult to uniformly measure and
define. Secondly, many of the approaches
neglected cumulative effects of the envi-
ronment on disease development, being
interested only in genetic component, al-
though most of those diseases show rat-
her low heritability and the majority of
cases in general population may be due to
environmental exposures. Thirdly, an ap-
pealing concept of »common disease/
common variant« (CD/CV) gained popula-
rity among the mainstream researchers
in the field, based on the assumption that
frequent diseases will be determined
mainly by genetic variants common to all
affected people from different human po-
pulations60.
The outcomes of the research based on
previous assumptions were not spectacu-
lar. This is not to say that there were no
successes. Due to large investments, ma-
ny small successes have been made and
the research field is rapidly expanding.
However, the massive undertaking of
poorly designed genetic association stud-
ies based on possibly false assumptions
resulted in a great number of reported as-
sociations of common diseases to numer-
ous genes across the genome, but the sub-
stantial portion of published reports is
likely to be false-positive. Therefore, the
issues of repeatability and interpretation
of such associations slowly became nearly
as important as conducting the studies
themselves61–63. It is beyond the scope of
this paper to list all the encountered ge-
netic associations, but some general con-
clusions can be drawn. The variants that
show repeatable associations with com-
mon diseases in more than one popula-
tion are usually of very small effect and
not always common in populations under
study. Those variants are therefore unli-
kely to individually explain substantial
proportion of disease burden in studied
population. Other variants that were im-
plicated but not repeated may also be
causal, but specific of the population un-
der study (e.g., an unusual gene-environ-
ment interaction in studied population).
Genetic architecture of common diseases
is slowly beginning to reveal a large di-
versity of potential genetic causes, all of
them acting through somewhat limited
number of mechanisms, with increasin-
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gly appreciated contribution of the envi-
ronmental interactions3,44.
Several individual efforts, however,
increased our understanding of genetic
basis of complex polygenic diseases to the
extent worthy of specific mention. We will
limit the presented examples to cardio-
vascular diseases and cancer only, as those
two complex diseases are jointly responsi-
ble for up to 75% of deaths in western
countries and therefore represent the
principal interest. The first example is
the study by Ozaki et al.64, in which about
1,000 cases of myocardial infarction (MI)
were compared to roughly as many con-
trol individuals using 92,788 gene-based
single-nucleotide polymorphism markers
(SNP). The authors used this impressive
number of markers in a nearly ideal high-
tech genetic association study, conducted
in a relatively genetically homogenous
Japanese population. Although they cov-
ered about half of the entire human geno-
me with their SNP markers, they could
only find one statistically significant as-
sociation (coding region of LTA gene on
chromosome 6) when recessive mode of
inheritance was assumed, and no signifi-
cant association (p<10–6) under a domi-
nant model. The increase in risk of vari-
ant carriers was modest, i.e. about 1.7.
Although presented as a success, this stu-
dy was actually rather discouraging for
the proponents of genetic association stu-
dies that are based on extremely large
numbers of SNP-markers, reasonable
samples of cases and controls from the
outbred general population and linkage
disequilibrium. Even if the reported asso-
ciation is truly causal, it is certain that
there must be far more genes underlying
MI risk, but they were not identified even
in this exercise that was massive in scale.
Another interesting effort is the one
performed by deCODE Genomics compa-
ny in Iceland population. This company
was founded in 1996 with aim to identify
the genetic causes of common diseases
and to develop new drugs and diagnostics
based upon its research. It used different
approach from the one presented above,
based on appreciating the large genetic
heterogeneity and complexity underlying
common diseases. Iceland population was
chosen as it offered most of the potential
advantages needed to tackle this com-
plexity – reduced genetic diversity, avail-
able disease data and reliable genealogi-
cal information. deCODE invested
hundreds of millions of dollars into at-
tempts to identify major genes involved
in more than 20 of the most common dis-
eases, and has successfully isolated genes
in seven of these to date, which is possib-
ly the greatest success rate by any group
in the world. The two very recent exam-
ples related to cardiovascular disease are
identification of the gene encoding phos-
phodiesterase 4D on chromosome 5 as a
risk factor of ischaemic stroke65, and the
gene encoding 5-lipoxigenase activating
protein on chromosome 13 as a risk factor
for MI and stroke66.
The investigations of genetic basis of
cardiovascular diseases are still at reaso-
nably early stage. However, the research
into genetic changes found in human can-
cers has been conducted for decades67.
The extreme diversity and complexity of
causes, mechanisms and consequences
underlying malignant transformation of
human cell is possibly a good predictor of
what will be encountered in the future
when studying genetic basis of other com-
plex diseases68. It is now known that fa-
milial (monogenic) forms of cancer, such
as breast cancer cases »exclusively« due
to BRCA1 and BRCA2 mutations, ac-
count for only about 20% of the familial
breast cancer cases, while familial cases
constitute only about 5–10% of all breast
cancer cases in general population. Even
among those »monogenic« breast cancers,
only 25% can be explained by changes in
BRCA and other known »breast cancer«
genes, while the remaining 75% of famil-
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ial cases are due to unknown familial pre-
disposing genes. Non-familial cases,
which constitute 90–95% of cases in gene-
ral population, can therefore be explained
only through interaction of unknown po-
lygenic predisposing genes and environ-
mental factors69.
Some of the changes in genetic mate-
rial that are frequently postulated as oc-
curring in tumour cells, although neither
necessary nor sufficient in all cases in po-
pulation to lead to cancer, are mutations
in coding or regulatory sequences, chan-
ges in overall ploidy, high amplification,
structural rearrangements and loss of he-
terozygosity67. The key feature of malig-
nant cells is genomic instability, which
can be due to inherited mutations in ge-
nes that monitor genome integrity, or ac-
quired in any somatic cell during the de-
velopment of cancer70. However, the
processes that follow are mediated
through and extreme diversity of mecha-
nisms, where it is difficult to distinguish
the changes that led to cancer from the
changes that arose as a consequence of
cellular transformation. The amount of
published results in cancer research that
is becoming available on different molec-
ular genetic aspects of the disease in re-
cent years is so vast, that possibly the
leading current problem seems to be inte-
grating and coordinating this knowled-
ge68. It is hoped that many discovered sig-
naling pathways act in parallel through
organized networks, but the only way to
find those universal principles that are
somewhat more limited in number is to
combine models and experiments. To ac-
hieve this, developing the system of cate-
gorization of knowledge will be essential,
and one such effort is represented in the
National Cancer Institute’s Cancer Geno-
me Anatomy project68. It is probable that
the experience with cancer genetics and
genomics will soon be repeated through
research into genetic causes of other com-
plex chronic diseases of late onset that we
did not mention here (e.g. psychiatric dis-
orders, type II diabetes, and others).
Current Understanding of Genetic
Architecture of Common Complex
Diseases
There is still a lot of uncertainty and a
great deal of controversy over understan-
ding of genetic architecture underlying
complex chronic diseases of late onset.
These diseases occur mainly in post-rep-
roductive period, and their genetic deter-
minants are therefore less subjected to
selective impacts from the environment
than is the case with more simple (mono-
genic and oligogenic) diseases of early on-
set. However, cumulative negative im-
pacts of the environment over time are
also more important in aetiology of late-
onset diseases than in early onset disea-
ses. Late-onset diseases are therefore not
only genetically more complex, but also
multifactorially determined. The key
questions that gave rise to recent debates
are about the frequency of the responsib-
le susceptibility variants in a population
(common / rare), on the number of loci in
the genome that underlie these diseases
(oligogenic / polygenic), and on the size of
their effects (large / small).
Some argue that, because the diseases
of late onset are quite common in a popu-
lation, their genetic determinants (vari-
ants responsible for increased susceptibi-
lity) should, intuitively, also be common
and therefore evolutionary rather old.
This is known as the »common disease –
common variant« hypothesis (CD/CV)60.
If this were true, genetic association stu-
dies would be expected to be successful
and to lead to identification of susceptibi-
lity variants. Others, however, argue
that, although counter-intuitively, com-
mon diseases are more likely to be caused
by highly complex interaction of numer-
ous genetic variants, most of them very
rare, interacting among themselves and
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with the environment. This hypothesis is
known as »common disease – rare vari-
ant« hypothesis (CD/RV), and would lar-
gely undermine currently proposed efforts
to identify disease susceptibility genes
using genetic association studies3.
Let us begin with what is known on
patterns of human genetic diversity, as it
is thought that diversity in variants we
carry in our genomes makes some of us
susceptible to specific late-onset diseases.
Firstly, more than 99% of our genome se-
quence there is practically no diversity,
and the variants at those loci are fixed
(i.e. have a population frequency of 100
%). However, the figure of 100% is not en-
tirely accurate, as it is possible that virtu-
ally any single nucleotide in this »invari-
ant« part of the genome may be changed
(»mutated«) in any individual. However,
this is not considered a true polymor-
phism, as such mutations have incredibly
low population frequencies, i.e. practical-
ly one in a number equaling twice the to-
tal human population size for those oc-
curring the first time in autosomal part of
the genome. Such newly arisen single nu-
cleotide polymorphism (SNP) would have
to increase its frequency over the course
human population history from 1 in hun-
dreds of millions of people to 1 in 100, e.g.
6–7 orders of magnitude, to become a true
polymorphism in the population. If that
occurred, this SNP can be considered a
»common« variant. It is predicted that
about 12 million single nucleotides in the
genome, i.e. less than 1%, should be po-
lymorphic33,71. This magnitude of increa-
se in population frequency for the newly
introduced mutations should only be pos-
sible through 2 general mechanisms: long-
time random genetic drift, or positive se-
lection favouring the carriers in each new
generation due to beneficial effects of
such mutation in a pre-reproductive life.
Going back to the »monomorphic« (»in-
variant«) majority of the human genome,
it is possible that even this part could
confer the susceptibility for development
of late-onset diseases. In that case, all the
humans would eventually get the disease
after being exposed to their environments
for sufficiently long periods. The differen-
ce in age of onset of the disease cases
would be determined solely by cumulati-
ve exposure to environmental risk factors
during lifetime. This is a »common disea-
se-fixed variant« hypothesis (CD/FV),
and there are good examples and plausib-
le explanations why this would be the ca-
se for some diseases42. For example, it is
very likely that starvation was a major
selective pressure during most of human
history, and that selection strongly favou-
red new variants that were protecting hu-
mans from hunger through more efficient
food metabolism. If those variants beca-
me fixed, and everyone in the present hu-
man population possesses them, the large
environmental change in which food be-
came easily accessible in supermarket
chains of the western world over the past
50 years would be expected to lead to a
pandemic of obesity. This scenario is in-
deed being observed nowadays. It is likely
that atherosclerosis is another example
of an »universal« disease, the developme-
nt of which depends only upon the sum of
environmental effects during lifetime.
Two important implications of »CD/
FV« hypothesis should be noted. Firstly,
it is useless to search for extremely rare
variants in this nearly »invariant« part of
the genome that would additionally in-
crease risk for e.g. obesity or atheroscle-
rosis above the »universal« risk shared by
everyone. This is because population at-
tributable fraction of disease cases due to
those specific variants would be negligib-
le and would not lead to any feasible pre-
vention of treatment strategies. Secondly
it is apparent that changing behaviour
and reducing risky environmental expo-
sures would have much larger public
health effects than any improvement in
understanding of genetic basis of disea-
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ses under CD/FV hypothesis. It is possib-
le that fixed variants indeed do play an
important role in genetic architecture of
many common complex diseases of late
onset, which could partly explain low ge-
netic variance and high environmental
variance in many of complex traits and
diseases.
However, for other complex diseases of
late onset, such as some types of cancer,
psychiatric and neurological diseases, it
is clear that a significant heritability can
be noted, and it is improbable that all the
humans would eventually develop those
diseases after enough time. In such disea-
ses (e.g., breast cancer, manic depression
or multiple sclerosis), genetic factors are
likely to play an important role in disease
predisposition. As there is variation among
humans in their predisposition to develo-
ping those diseases, it is thought that this
variation is mediated through polymor-
phic sites in the genome. The key ques-
tion, however, remains whether the pre-
disposition to disease is a result of action
of variants at several loci (oligogenic ge-
netic architecture), all of which carry rea-
sonably large relative risk (e.g. RR>2.0)
and are common in a population (CD/CV
hypothesis). The alternative hypothesis
is that there are many loci across the ge-
nome that interact among themselves
and with the environment (polygenic ge-
netic architecture), most of which carry
very small relative risk associated to in-
dividual variants (e.g. RR<1.5) are very
rare in a population (CD/RV hypothesis).
Under the first model, identification of
several responsible variants of large ef-
fect would certainly provide clues into di-
sease pathogenesis, and enable genetic
screening, prevention and gene-based
therapy. Under the second model, the
identification of individual rare genetic
variants that marginally increase disease
risk would contribute very little to under-
standing of disease pathogenesis and
would not lead to feasible diagnostic and
therapeutic advances.
The two hypotheses are not necessari-
ly mutually exclusive, and there are ar-
guments to support both. Lohmuller et al.
reviewed the replicated gene-disease as-
sociations in the world literature, the as-
sociated relative risks and the frequen-
cies of the implicated variants in the
population, and concluded that there is
support for CD/CV hypothesis72. Howe-
ver, the associated relative risks were
usually overestimated in first published
reports and they appear rather small, so
that the identified associations largely
failed to improve the understanding of
disease pathogenesis. It is still thought,
however, that the general lack of success
in mapping complex disease genes is due
to most of the current studies being under-
powered (using too few cases and genomic
markers to detect associations), and that
improved designs and meta-analyses should
detect more common variants8,73,74. Others
doubt that even the increase in number of
subjects or number of markers should ne-
cessarily help3. They argue that if the va-
riants became common in a population,
they are likely to either be neutral during
pre-reproductive period (and thus increa-
sed in frequency by genetic drift), or to
have beneficial effects on fitness in pre-
reproductive period (and therefore be po-
sitively selected). This would imply that
common variants with detrimental ef-
fects in post-reproductive period would
have had to be evolutionary very old and
neutral or even beneficial (»antagonistic
pleiotropy« hypothesis) in early life. The
authors consider this unlikely, based on
summary of the evidence from experi-
mental organisms, or at least not a lead-
ing mechanism of common disease patho-
genesis. Finally, there is a third scenario
in favour of CD/CV hypothesis which can-
not be easily dismissed. It hypotheses
that some very rare variants became ex-
tremely useful in times of large pandem-
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ics of infectious diseases, and rapidly in-
creased in frequency over shorter periods
of human history. A detrimental variant
that was physically close (in tight linkage
with) the protective variant could then al-
so increase in frequency via »hitch-hik-
ing« effect, as its detrimental effects on
fitness were considerably smaller than
the beneficial effects of the linked protec-
tive variant under the selective pressure
of epidemics. This could explain at least
some of the numerous reported associa-
tions between specific HLA groups and
some relatively common human disea-
ses75.
The proponents of CD/RV hypothesis
use mainly arguments that rely on deca-
des of fundamental research in popula-
tion genetics and human evolution. As
the human population underwent a mas-
sive expansion over the past several gen-
erations, modelling the predicted number
of newly arisen mutations during recent
human history implies that the majority
of genetic variants contributing to curre-
nt human genetic and phenotypic varia-
tion is predicted to be rare3. This argu-
ment has recently been strengthened by
the discovery that the estimate of the
number of mutations per generation per
gamete could have been historically un-
derestimated by an order of magnitude76.
The recent work by Cohen et al. is the
first highlighted paper that empirically
shows that a risky tail of the distribution
of a complex quantitative trait – HDL
cholesterol – is determined mainly by ra-
re variants at the population level77. Al-
though it may seem counter-intuitive to
some scientists (and certainly less attrac-
tive for industrial investment) that com-
mon diseases of late-onset are mainly
caused by a large number of rare variants
with small effects, this long neglected
view appears to finally be gaining some
support.
To summarise the current state in this
debate, it is generally accepted that the
allelic frequencies in the population and
their effect size have an »L«-shaped dis-
tribution. The alleles with very large ef-
fects, that could provide new insights into
disease pathways and mechanisms, are
predicted to be very rare in the popula-
tion. At the same time, the alleles with ti-
ny effects in pre-reproductive period are
allowed by selection to become more com-
mon78. Unless antagonistic pleiotropy is a
very general mechanism, or many selecti-
vely neutral variants tend to become de-
letorious in post-reproductive period, it is
most likely that ageing process, accompa-
nied with the development of complex
chronic diseases of late onset, is mainly
mediated by »mutation accumulation«
hypothesis. Under such model, the effects
of many rare and possibly some common
variants interacting among themselves
and with the environment would cumula-
tively lead to the breakdown of intrinsic
compensation mechanisms of human or-
ganism and eventually manifest as the
disease phenotype.
Leading Current Approaches
to Identify Common Complex
Disease Genes
Based on everything discussed so far,
is can be concluded that two main com-
prehensive approaches to identify com-
mon complex disease genes are emerging
in the post-genome sequence era. The
first approach, which currently has a role
of the mainstream research due to large
number of publications of its proponents
in high-profile journals in recent years, is
advocating high-spending efforts in gene-
ral population of western countries, such
as U.K. and U.S.A. (»BioBanks«)79,80. Such
studies would attempt to generate large
population cohorts (of up to 1 million peo-
ple) with great quantities of information
on individual genetic background and en-
vironmental exposures. Then, massive
genetic association studies would be de-
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signed with tens (or even hundreds) of
thousands of affected cases and unaffec-
ted controls. Their genomes would be se-
quenced using the large number of single-
nucleotide polymorphisms (SNP), which
may run into hundreds of thousands of
markers per person. The key assumption
that would eventually determine the suc-
cess of this general approach is that the
genes underlying most common complex
diseases and their underlying haplotypes
are common in the population (common
disease/common variant hypothesis, »CD/
CV«). Recent meta-analysis of genetic as-
sociation studies published to date was
supportive of significant contribution of
common variants to common disease sus-
ceptibility72. The leading current effort
following this direction is the »Internatio-
nal Hap-Map Project«81. This project as-
sumes that most of the human genomic
diversity is common, organised into dis-
tinct »haplotype blocks« which are also
common, and so are the disease suscepti-
bility mutations arising on those blocks.
Ultimately, the catalogue of all variants
of haplotype blocks in the human genome
would enable associating them with com-
mon diseases, which would be more feasi-
ble strategy than genome-wide scan if the
initial assumptions are correct. Moreo-
ver, each haplotype would be defined by a
minimum informative number of SNP’s
needed to distinguish it from other haplo-
type variants (»haplotype tagging«), which
would greatly reduce the costs and effort
of genotyping82.
An alternative approach is based on
assumption that the key to success in
mapping complex disease genes will be
through decreasing their aetiologic heter-
ogeneity and improving correlation be-
tween genotypes and phenotypes in popu-
lation under study. This approach
advocates the use of isolate human popu-
lations with defined number and origin of
founders, known ethnic history, possibili-
ty to define disease phenotypes and re-
construct individual genealogical re-
cords39,83. Some of the obvious advanta-
ges of this approach is that it is orders of
magnitude less costly, and that linkage
analyses and genetic association studies
can be performed at the same time to sup-
port each other and increase the power of
the study. However, the main advantage
may be that this approach should work
even if the variants underlying common
complex diseases are rare in general pop-
ulation. This is because such rare vari-
ants with large effects may still be com-
mon enough in an isolate population to be
detected by genetic association study. If
they are also rare in an isolate popula-
tion, they still may be detected by linkage
analysis, through an approach that is si-
milar to mapping of monogenic (Mende-
lian) diseases in isolate populations, whi-
ch already proved successful in the past.
Therefore, even if most of the genetic di-
versity underlying common diseases pro-
ves to be rare, which is somewhat counter-
intuitive but predicted by population ge-
netic theories (common disease/rare vari-
ant hypothesis, »CD/RV«), the variants
could still be identified3. The problem
with studying isolate populations is that
the results may not be relevant for and
applicable to wider, general populations.
However, it seems that this approach is
recently being taken more seriously in
the research community due to recent
successes in Iceland65,66. This is especial-
ly true because Iceland’s most recent suc-
cess, finding a gene that increases sus-
ceptibility to myocardial infarction, was
mapped on a rather common haplotype in
Iceland. The association with the suspec-
ted genomic location was later confirmed
in the population of United Kingdom by
candidate gene approach and genetic as-
sociation study, but with different and
less common haplotype involved in the
latter population, which casts doubt if the
initial finding would be possible in the
U.K. population. The results from other
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isolate populations that are currently un-
der study are eagerly expected, which in-
clude populations of Newfoundland84,
Saami85, Sardinia86, Israel87, Nether-
lands88, Croatia89–96 and Dagestan97, to
mention a few.
In addition to those two leading ap-
proaches that are attempting to discover
genetic variants underlying complex com-
mon diseases in a comprehensive way,
and to find genes for many different dis-
eases and traits within the same study,
there are also other, more specific ap-
proaches that led to important advances.
Many disease-oriented groups through-
out the world formed multi-centre initia-
tives to gather large number of patients
with a specific diagnosed disease of inter-
est. In such cases, unlike in the two ap-
proaches mentioned above, the recruit-
ment of the disease cases is not popu-
lation-based, but rather hospital-based.
When an adequate number of cases is rec-
ruited for the study, the gene is initially
sought for by either »transmission-dis-
equilibrium test« (TDT) in disease cases
only, which requires DNA from both par-
ents regardless of their disease status, or
by linkage analysis in expanded pedig-
rees of the cases. The latter approach is
especially powerful if there are multiple
cases in the families of the recruited pa-
tients, and if the diseases in collected ca-
ses were of early onset. When a significant
»LOD-score« (statistical measure of asso-
ciation between genomic locus and mea-
sured phenotype) is obtained at one or
more loci in the genome (the threshold is
usually set at LOD=3.0), those regions
become »candidate regions« that may
harbour a gene responsible for disease
susceptibility. The next step is recruiting
another large and independent sample of
disease cases in the same hospitals and
checking if those »candidate regions« are
again associated with the disease status
in this new sample of patients, thus reaf-
firming or dismissing the importance of
the loci implicated in the first study. This
general approach, although only single
disease specific, subject to number of con-
founding effects (such as population stra-
tification)98) and often disregarding envi-
ronmental effects, has still been quite
successful. Many of the repeatable associ-
ations in the current literature were re-
ported after this initial approach99,100.
Translating Genomic Knowledge
into Public Health Benefits
There are two main expectations from
genetic epidemiology in terms of deliver-
ing results that would have major impact
on public health. The first one is the asso-
ciation of different genetic variants with
specific health risks and the translation
of that knowledge into development of
commercially available genetic tests that
could predict diseases. The second one is
the understanding of disease mecha-
nisms and obtaining new insights in dis-
ease pathogenesis, which would reveal
new targets for development of drugs
that could prevent or reverse the course
of human diseases101. Although several
years ago those targets appeared far from
reality, today there is a growing economic
sector of biotechnology, in which large
number of private companies are attem-
pting to deliver one or both of those goals,
and some tests and genome-based drugs
are already being offered on the market.
We will briefly address the current status
of advancement towards those two main
goals of genetic epidemiology.
In terms of genetic testing, recently al-
so called »genomic profiling«, it is based
on an expectation that knowing most of
genetic variants that could increase the
risk of disease would enable the develop-
ment of »DNA chips« containing this in-
formation. Those chips could then scan
for the presence of extremely large num-
ber of such variants in any individual’s
genome at birth. After the scan of the ge-
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nome, the chip would compute the lifeti-
me risk of various diseases, thus being a
powerful tool of a »personalised medici-
ne«. Although a number of private com-
panies already offer genomic profiling for
»oxidative stress«, »susceptibility to obe-
sity or osteopenia«, »nicotine or alcohol
dependance«, etc., these could hardly ha-
ve any scientific basis, as the genetic ar-
chitecture of those traits and responsible
variants are simply not known with any
accuracy at present. Therefore, the prob-
lem of regulating the marketing of such
tests is growing recently, as it is entirely
unlikely that we could have useful and
reliable genetic tests that could predict
individual risk of common complex disea-
ses in foreseeable future101. However, in
the meanwhile it is certain that the ease
of marketing of those tests (internet) cou-
pled with the desire of consumers in some
western countries to actively control their
health at any cost may result in creation
of smaller market for these tests of un-
proven value. Similar or even more dra-
matic examples have already been seen
with the popularity of various diets and
food supplements20,21,102,103.
However, although predicting complex
diseases in individuals based on their
unique genome sequence may still be far
from reality, there have been some positi-
ve developments in achieving the second
target – associating genes with diseases
to understand aetiology which eventually
led to new drug discoveries. The two fre-
quently cited examples are imatinib and
trastuzumab104,105. Imatinib (Gleevec)
was developed following the discovery
that a chromosome translocation created
a new gene structure in some patients
with chronic myeloid leukaemia, and the
drug binds to the protein product of this
gene and fights disease progression whe-
re other treatments fail104. Trastuzumab
(Herceptin) did not appear to significan-
tly improve survival of breast cancer pa-
tients, until it was realised that it is very
efficient, but only in a subset of Her-2 po-
sitive breast cancer cases. Although those
examples based on molecular understan-
ding of disease pathogenesis may seem
spectacular, the more general view is that
the successes in finding the genes under-
lying common complex diseases have
been very modest in relation to unprece-
dented investments into this research
from both industry and academic commu-
nity. Although numerous associations of
various genes with a spectrum of diseases
have been reported, only a few of those
associations have been replicable. Moreo-
ver, the risks associated to implicating
variants were usually very modest and
promising little hope for contributing to
improvement in understanding of disease
aetiology. As the current level of invest-
ment in unsustainable, it is becoming ap-
parent that the successes in mapping ge-
nes for Mendelian diseases will not be
easily repeated with complex diseases,
and that more rational strategies for as-
sociating genes and disease phenotypes
will need to be developed.
Based on this premises, the recent re-
view by Merikangas and Risch106 provi-
ded a more sober assessment of the cur-
rent status of search for common complex
disease genes and strategies for future in-
vestments. The authors argue that inves-
tments are justified for the diseases that
are: (i) common in the population (associ-
ated with substantial public health bur-
den); (ii) can be precisely diagnosed (to
avoid misclassification of cases, which
dramatically reduces power of genetic as-
sociation and linkage studies); (iii) show
substantially increased risk in relatives
of diseased cases (to demonstrate the role
of genetic effects as opposed to environ-
ment); and (iv) for which no preventable
environmental risks are known. It is wor-
rying that enormous funds are being in-
vested in searching for genetic basis of di-
seases or conditions that hardly show any
heritability, cannot be diagnosed with
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any precision, or for which the funds
would be far better placed in fighting en-
vironmental risks rather than searching
for genetic clues. For example, investing
funds in finding genes for increased indi-
vidual »nicotine dependence« or »alcohol
dependence« is entirely misplaced, as
those traits have been shown to cluster
more strongly in social groups of different
genetic background rather than in fami-
lies. In addition, the benefit of public
health intervention on reducing nicotine
and alcohol consumption in a population,
which are cheaper than gene searches,
far outweigh any possible benefit that
could come out of knowing genes that pre-
dispose an individual to alcohol consump-
tion or smoking. The large majority of ca-
ses of coronary heart disease or diabetes
type II in population can be explained by
environmental risks such as unhealthy
diet, lack of physical activity and smok-
ing. It is unlikely that finding genetic va-
riants that mildly increase risk of those
diseases, and even developing therapies
based on that knowledge, would lead to
appreciable decrease of their public health
burden in a population.
The examples of diseases where geno-
mic revolution could prove helpful, howe-
ver, are Alzheimer’s disease, multiple
sclerosis, autism or schizophrenia, where
relatives of diseased are clearly at grea-
ter risk, there are no known preventable
environmental risks and which are suffi-
ciently common in the population to justi-
fy large investments. For other diseases,
the funds would be better placed into re-
search of determinants of human behav-
iour and motivation for leading more
healthy lifestyles. This is all particularly
relevant for the population of western
countries, where an estimated 150 mil-
lion people already have type II diabetes
and are overweight. However, only a mi-
nority of world’s population lives in devel-
oped countries. In recent years, calls have
been made upon international scientific
community not to forget the majority of
world’s population that does not represe-
nt a lucrative market for pharmaceutical
industry, but could also perhaps benefit
from new genomic and molecular technol-
ogies, even more than the western world107.
The facts that 11 million children under
five years still die annually of mainly pre-
ventable or easily treatable causes, such
as pneumonia, diarrhoea, malaria or mal-
nutrition, and that more than two thirds
of people with AIDS live in countries with
virtually non-existent health systems,
are more than worrying. Those people
could greatly benefit from recombinant
vaccines that use genomic technology, or
also from molecular tests that could pre-
cisely diagnose the aetiology of their in-
fections and thus enable more efficient
use of sparse medicines available to those
populations. It remains to be seen whet-
her the genomic revolution of 21st century
will truly revolutionise medicine and re-
sult in major public health benefits for all
of the humanity. The alternative scenario
is that it may only deliver partial succes-
ses which will become available to the
rich minority and thus further increase
the gap between the world’s rich and the
poor, as was the case with recent revolu-
tions in informatics and telecommunica-
tion technologies in 1980’s and 1990’s.
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OD NAPRETKA U ISTRA@IVANJU GENOMA DO JAVNO-ZDRAVSTVENE
DOBROBITI: NEPODNO[LJIVA LAKO]A STAJANJA U MJESTU
S A @ E T A K
Genetske odrednice ~estih ljudskih bolesti jo{ uvijek su slabo razja{njene. Zahvalju-
ju}i golemim ulaganjima, u~injen je niz manjih napredaka i znanstveno podru~je se
ubrzano razvija. Me|utim, identificirane genetske varijante koje pokazuju ponovljivu
povezanost s kompleksnim bolestima su obi~no slabog u~inka. Stoga nije vjerojatno da
}e pojedina~ne genske varijante razjasniti zna~ajan dio morbiditeta u zajednici ili pak
pru`iti nove uvide u patogenezu bolesti koji bi mogla dovesti do razvoja novih lijekova
primjenjivih na zna~ajniji udio oboljelih u populaciji. Genetska arhitektura ~estih bo-
lesti po~inje razotkrivati veliku raznovrsnost potencijalnih genetskih uzroka koji dje-
luju kroz pone{to ograni~en broj mehanizama uz va`an utjecaj interakcija s okoli{em.
U svjetlu spomenutih otkri}a, u ovom smo radu prikazali sada{nje razumijevanje ge-
netske arhitekture cijelog spektra ljudskih bolesti. Osvrnuli smo se na probleme koji
su proiza{li iz poku{aja pronala`enja gena odgovornih za sklonost bolestima, izvr{ili
kratak pregled uspje{nosti vode}ih strategija za identificiranje gena, te razmotrili per-
spektive za prevo|enje napretka u genomskim istra`ivanjima u mjerljivu javno-zdrav-
stvenu dobrobit.
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